![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 44, 41954-41959, November 1, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Biophysical Chemistry, Lund University,
Chemical Centre, P.O. Box 124, S-221 00 Lund, Sweden
Received for publication, April 11, 2002, and in revised form, July 10, 2002
Calbindin D28k (calbindin) is a
member of the calmodulin superfamily of Ca2+-binding
proteins. An intracellular target of calbindin was discovered using
bacteriophage display. Human recombinant calbindin was immobilized on
magnetic beads and used in affinity purification of phage-displayed peptides from a random 12-mer peptide library. One sequence,
SYSSIAKYPSHS, was strongly selected both in the presence of
Mg2+ and in the presence of Ca2+. Homology
search against the protein sequence data base identified a closely
similar sequence, ISSIKEKYPSHS, at residues 55-66 in myo-inositol-1(or 4)-monophosphatase (IMPase, EC 3.1.3.25), which constitute a strongly conserved and exposed region in the three-dimensional structure. IMPase is a key enzyme in the regulation of the activity of the phosphatidylinositol-signaling pathway. It
catalyzes the hydrolysis of myo-inositol-1(or
4)-monophosphate to form free myo-inositol, maintaining a
supply that represents the precursor for inositol phospholipid second
messenger signaling systems. Fluorescence spectroscopy showed
that isolated calbindin and IMPase interact with an apparent
equilibrium dissociation constant, KD, of 0.9 µM. Both apo and Ca2+-bound calbindin was
found to activate IMPase up to 250-fold, depending on the pH and
substrate concentration. The activation is most pronounced at
conditions that otherwise lead to a very low activity of IMPase,
i.e. at reduced pH and at low substrate concentration.
Calbindin D28k
(calbindin)1 is a highly
conserved member of the calmodulin super family of EF-hand proteins,
containing 261 residues and 6 EF-hand motifs. It is expressed in many
tissues including brain, intestine, kidney, and pancreas. Many reports have focused on the presence of calbindin in specific neuronal cell
types in the brain and sensory system (1-3). It constitutes as much as
0.1-1.5% of the total soluble protein in brain (4), and in some cells
it may be present at intracellular concentrations of up to 2 mM (5).
The protein has been demonstrated to protect neurons against
excitotoxic cell death (6) and spares neurons from apoptotic cell
death following ischemic insults or epileptic seizures where damage is
believed to occur from Ca2+ overload (7, 8).
Calbindin is of further importance for motor coordination in mice (9)
and has been suggested to restrict evoked Ca2+ signals in
nerve synapses and hair cells (10, 11). Most of these results have been
explained by the proposed function of calbindin as a potent
intracellular Ca2+-buffering protein. Whether or not
calbindin has additional regulatory functions similar to the
prototypical Ca2+ sensor calmodulin is currently under
debate. To date, there are only a few reports describing specific
in vitro effects of calbindin on enzyme systems
(12-14).
Our earlier work has shown that calbindin has exposed hydrophobic
surfaces both in the apo and Ca2+ form (15). Exposure of
hydrophobic surfaces to water is thermodynamically unfavorable, and it
is therefore likely that calbindin uses these surfaces to interact with
other cellular proteins. In the present work, we have searched for
potential targets of calbindin by affinity purification of
a phage display library of random 12-mer peptides against immobilized
calbindin. One sequence, which was strongly selected in the presence of
either Mg2+ or Ca2+, was used in a homology
search against the protein sequence data base. A strong match was found
with residues 55-66 in myo-inositol-1(or 4)-monophosphatase
(IMPase). IMPase catalyzes the dephosphorylation of
myo-inositol monophosphates (myo-inositol 1-P and
myo-inositol 4-P) to release inositol, which is used to
regenerate phosphatidylinositides (PIs), key components in the PI
signaling pathway (16). Activation of this pathway produces two
important intracellular messengers, myo-inositol-1,4,5-triphosphate (IP3) and
diacylglycerol. IP3 is a water-soluble molecule that
diffuses through the cytosol and releases Ca2+ from
intracellular stores by binding to IP3-gated
Ca2+ release channels. Diacylglycerol remains bound to the
plasma membrane and activates protein kinase C, a crucial enzyme that regulates many target proteins through phosphorylation. Although the
enzymatic function of IMPase and its structural properties are
relatively well characterized, surprisingly little is known about
the regulation of the enzyme. Here we show that calbindin and IMPase
bind to each other with a KD of ~1
µM and that calbindin increases the phosphatase activity
of IMPase.
Materials--
Human recombinant calbindin was expressed in
Escherichia coli and purified as described (17). The apo
form of calbindin was prepared using gel filtration of protein/EGTA
mixtures (15). IMPase was purified from bovine brain using ammonium
sulfate precipitation, heat treatment, and phenyl-Sepharose
chromatography, as described in detail
elsewhere.2 Rat recombinant
calretinin and human recombinant secretagogin were gifts from
Patrick Groves and Malgorzata Palczewska (Nencki Institute, Warsaw,
Poland). myo-Inositol-1-monophosphate from soybean was
purchased from Sigma and Tween 20 from Riedel de Hahn. The Ph.D.-12
Phage Display Peptide Library kit was obtained from New
England Biolabs. The kit contains a random peptide 12-mer phage display
library, E. coli ER2738 host strain for phage amplification, and a sequencing primer (5'CCCTCATAGTTAGCGTAACG). Additional primer of
the same sequence was purchased from DNA Technologies (Aarhus, Denmark). Dynabeads M-280 were from Dynal Biotech (Oslo,
Norway). Sulfosuccinimidyl-6-[biotinoamido]hexanoate (NHS-LC-biotin),
biotin (immuno pure), bovine serum albumin (immuno pure, fraction V), 2-(4'-hydroxyazobenzene) benzoic acid (HABA), and avidin were from
Pierce. All buffers and other chemicals were of analytical grade.
Synthetic peptides with acetylated N terminus and amidated C terminus
were purchased from Malmö General Hopsital, department of
Clinical Chemistry (ISSIKEKYPSHS), and Medprobe (Oslo, Norway) (SYSSIAKYPSHS).
Phage Display--
Phage display studies were carried out as
described in detail in the manual provided with the Ph.D.-12 Phage
Display Peptide Library kit. In short, calbindin was conjugated to
NHS-LC-biotin and bound to magnetic beads covered with streptavidin
(Dynabeads M-280). The beads were then equilibrated with the phage
display library for 60 min. Parallel experiments were carried out in 50 mM Tris/HCl, pH 7.5, 150 mM KCl, 0.05% Tween
20 with either 1 mM CaCl2 or 1 mM
MgCl2 plus 100 µM EGTA. The beads were then
washed ten times with the respective buffer to remove weakly bound
phages, and the more strongly bound phages were eluted by washing the beads with 0.2 M glycine buffer at pH 2.2 containing 1 mg/ml bovine serum albumin. The eluates were neutralized by adding 1 M Tris/HCl, pH 9.1, and used to infect E. coli
ER2738 at mid log-phase (OD = 0.5). After 5 h of culturing,
phages were purified from the culture supernatant using PEG precipitation.
DNA Sequencing--
Phage eluate from the third round of
affinity purification was used to infect E. coli ER2738 and
spread on LB plates with isopropyl Interaction between Calbindin and IMPase--
The interaction
between calbindin and IMPase was studied in a quartz cuvette with 3 mm
path length using fluorescence spectroscopy. Excitation spectra were
recorded on a Perkin Elmer LS50B fluorescence spectrometer between 200 and 300 nm (bandwidth 2.5 nm) with emission at 331 nm (bandwidth 3 nm),
thus monitoring mainly tryptophan fluorescence. Two samples, one with
10 µM IMPase and one with 10 µM IMPase plus
20 µM calbindin, were mixed in different proportions to
obtain calbindin concentrations ranging from 0 to 20 µM.
A second series of samples contained calbindin at the same
concentrations, ranging from 0 to 20 µM, but no IMPase.
Fluorescence excitation spectra were recorded for each sample, and the
spectrum of each IMPase calbindin mixture was subtracted from the sum
of spectra recorded separately for IMPase and calbindin at the same
concentration. The resulting fluorescence difference,
CIMPase is the total IMPase concentration and
CCB the total calbindin concentration.
Interaction between Calbindin and Synthetic Peptides--
The
interaction between calbindin and synthetic peptides with the sequence
SYSSIAKYPSHS or ISSIKEKYPSHS was studied using fluorescence
spectroscopy in a similar procedure as described above but keeping the
calbindin concentration constant (10 µM) and varying the
peptide concentration (0-500 µM).
IMPase Activity--
The reaction buffer (50 mM
Hepes/KOH, 150 mM KCl, pH 7.1) was rocked for 1 week in a
plastic container with Chelex 100 (Bio-Rad) in a dialysis bag to reduce
the Ca2+ concentration followed by the removal of the
Chelex bag and addition of 2 mM MgCl2 or 100 µM EGTA and 2 mM MgCl2. A number
of stock solutions with different concentrations of IMP and calbindin
were prepared in the reaction buffer. IMP stock (50 µl) was mixed
with calbindin or a buffer blank (50 µl), and the reaction was
started by adding IMPase stock (100 µl) to yield a final
concentration of 0.02 µM IMPase, as estimated by acid
hydrolysis. The reaction was carried out at 37 °C between 20 and 240 min, depending on the substrate concentration and pH (see below). The
reaction was quenched by adding 20 µl of 12 M HCl
followed by a quick centrifugation step to pellet precipitated protein.
The supernatant (200 µl) was mixed with a chromophoric reagent (800 µl) and equilibrated for 30 min before 40 µl of 1.5% Tween 20 was
added and the absorbance at 660 nm recorded. The chromophoric reagent
was prepared by mixing 50 ml of 4.2%
(NH4)6MoO24·4H2O in 5 M HCl with 150 ml of 0.2% Malachite Green in
H2O. The solution was incubated for 30 minutes and then
filtered. The assay was standardized using potassium phosphate
(0.05-10 µM).
The first set of enzymatic assays were performed in the presence of 100 µM EGTA, and the concentration of Ca2+-free
calbindin was varied between 0.01 and 600 µM and the
substrate concentration between 2.5 and 320 µM. The
second set of experiments contained 100 µM EGTA, 40 µM IMP, and 0 or 10 µM calbindin. In these
experiments the pH of each stock solution was adjusted
prior to mixing to a defined value between 6 and 8, and the solution was kept on a pH electrode during mixing to ensure that the pH did not
drift. The third set of enzymatic assays was performed with 40 µM IMP, 0 or 10 µM calbindin, and no EGTA.
The total Ca2+ concentration was varied between 0.5 µM and 1 mM. The free Ca2+
concentration in the samples with calbindin was calculated using its
four macroscopic Ca2+-binding constants (15). In a fourth
set of experiments, the IMPase activity was compared for reaction
mixtures containing 0 or 100 µM EGTA. In a fifth set of
experiments, in 100 µM EGTA, the specificity of the
activation of IMPase by calbindin was examined by measuring the
activity of IMPase in the presence of various substances, peptides,
or proteins at different concentrations.
Phage Display Studies--
A random 12-mer peptide library
displayed on bacteriophage surface was used to search for sequences
with high affinity for calbindin. Peptides binding to human recombinant
calbindin were enriched in three rounds of affinity purification, with
intervening amplification of high affinity binding phages in E. coli. Parallel experiments were carried out in the presence of 1 mM Ca2+ or 1 mM Mg2+.
E. coli infected with the eluate from the third round were
spread on plates to obtain individual clones for DNA sequencing. In the presence of Ca2+, the sequence SYSSIAKYPSHS was strongly
enriched and found in 29 of 30 sequenced clones. In the presence of
Mg2+, the same sequence was dominating and found in 11 of
12 sequenced clones.
Homology Search--
The sequence SYSSIAKYPSHS was used in
homology search against the protein sequence data base using the Scanps
algorithm (www2.esi.ac.uk/scanps), revealing a strong match with
residues 55-66 in the 277-residue enzyme IMPase, ISSIKEKYPSHS.
Interaction between Calbindin and IMPase--
The interaction
between calbindin and IMPase was studied using fluorescence
spectroscopy as described in under "Experimental Procedures."
The IMPase concentration was kept constant at 10 µM, whereas the calbindin concentration was varied
between 0 and 20 µM, and a parallel series of samples
contained 0-20 µM calbindin but no IMPase. Significant
differences in tryptophan excitation fluorescence spectrum were
obtained when comparing calbindin-IMPase mixtures to the sum of spectra
recorded individually for the two proteins. The data at one wavelength
and computer fit is shown in Fig. 1. The
fluorescence difference reaches a maximum at close to 10 µM calbindin, indicating a 1:1 (or 2:2)
stoichiometry. The best fit was obtained using KD = 0.9 µM.
Interaction between Calbindin and Synthetic Peptides--
The
interaction between calbindin and synthetic peptides with the sequence
SYSSIAKYPSHS or ISSIKEKYPSHS was studied using tryptophan fluorescence
excitation spectroscopy. Similar spectral changes (sum
versus mix) were obtained as with intact IMPase but requiring larger peptide concentrations, indicating that
the binding was weaker (data not shown). Optimal fits to the data were
obtained with KD = 160 µM for the
SYSSIAKYPSHS peptide and KD = 330 µM
for the ISSIKEKYPSHS peptide. It may seem surprising to have purified a
peptide with such a low affinity for calbindin D28k.
However, each phage particle displays five identical copies of the
peptide. This allows the phage to interact with more than one
immobilized calbindin molecule to yield an apparent high affinity (avidity).
Effect of Calbindin on IMPase Activity--
The
dephosphorylation of IMP to produce inositol and phosphate was
monitored by 1H NMR spectroscopy. 1H NMR
spectra were acquired for 2 mM IMP at different time points after adding catalytic amounts of IMPase in the absence and presence of
50 µM calbindin. The dephosphorylation of IMP into
inositol was 4-fold faster in the presence of calbindin than in its
absence (data not shown). This indicates that the phosphatase activity of IMPase is enhanced by calbindin. The cellular concentration of IMP
is, however, around 20 µM, which yields poor NMR signals. Further activity measurements were therefore performed using a chromophoric method to quantitate released phosphate (18).
Using the chromophoric assay, the IMPase activity was measured in the
presence of 2 mM Mg2+ and 100 µM
EGTA to avoid perturbations from Ca2+ ions. Assays were
performed in the absence and presence of calbindin (0.01-600 µM) at substrate concentrations ranging
between 2.5 and 300 µM (Fig.
2). These data show that the activity of
IMPase is enhanced by the presence of calbindin. Half-maximal
activation is reached at calbindin concentrations of 1-10
µM. It also appears that the less substrate used the
larger the effect of calbindin (Fig. 2B).
Control Experiments--
No hydrolysis of IMP was observed in
control experiments with 100 µM calbindin but no IMPase.
No free phosphate was detected in reaction mixtures with 100 µM calbindin and 0.04 µM IMPase but no IMP.
The activity of IMPase was not enhanced in the presence of calbindin
digested with trypsin or pepsin (not shown). Calbindin digested with
trypsin or pepsin did not bind to IMPase (not shown). The activating
effect of calbindin on IMPase activity could be displaced by the
ISSIKEKYPSHS peptide (not shown), whereas the unrelated peptide
SGIAQFHIDYNNVS3 had no
effect. The activity of IMPase was also measured in the presence of the
proteins calretinin and secretagogin (19, 20), both of which contain
six-EF-hands and are homologous of calbindin, and in the presence of a
few other macromolecules (HIDYNNVS, SGIAQFHIDYNNVS, poly-D-glutamic acid, poly-L-lysine, PEG 4000, PEG 8000, cytochrome c, and calmodulin). At comparable
conditions, the IMPase activity in the presence of 25 µM
macromolecule divided by the activity of IMPase alone (the relative
activity) was 1.01 for calretinin, 0.99 for secretagogin, 1.06 for
HIDYNNVS, 0.99 for SGIAQFHIDYNNVS, 1.13 for poly-D-Glu,
0.94 for ploy-L-Lys, 1.00 for PEG 4000, 0.99 for PEG 8000, 1.20 for cytochrome c, 1.41 for calmodulin,
and 3.22 for calbindin. Small stimulatory effects on IMPase activity are hence observed in the presence of calmodulin, cytochrome
c, and poly-glutamic acid. All the other proteins and
substances, including calretinin and secretagogin, show no or
negligible activation of IMPase. The experiments were performed three
times using double samples, and the deviations were less than 5%.
pH Effect on IMPase Activity--
Using the chromophoric assay,
the IMPase activity was measured in the presence of 2 mM
Mg2+ and 100 µM EGTA at pH values ranging
from 6.0 to 8.0 (Fig. 3). The activity of
IMPase is steeply pH-dependent between pH 7 and 6, and the
activity is practically lost at pH 6 (Fig. 3A). No released
phosphate could be detected at pH 6 even after a 4-h reaction time. In
the presence of calbindin, the IMPase activity is only slightly reduced
below pH 7, and a significant level of activity remains at pH 6. Therefore, the relative activation by calbindin is larger the lower the
pH (Fig. 3B). At pH 6 the relative activation cannot be
calculated because no activity is observed in the absence of
calbindin.
Ca2+ Effects on IMPase Activity--
Using the
chromophoric assay, the IMPase activity was measured in the presence of
2 mM Mg2+ and variable Ca2+
concentrations (Fig. 4). The activity of
IMPase is reduced at Ca2+ concentrations above ~10
µM, and at 1 mM Ca2+ the activity
is lost. However, calbindin activates the enzyme significantly also in
the presence of Ca2+. The IMPase activity observed
at 400 µM Ca2+ and 10 µM
calbindin is comparable with that observed in the absence of both
Ca2+ and calbindin.
In this report we show that calbindin D28k interacts
with (Fig. 1) and activates IMPase (Fig. 2-4). The activation is
highly specific because calretinin and secretagogin, two hexa EF-hand proteins that are homologous to calbindin D28k (58 and 37%
sequence identity, respectively), do not have any observable effect on the activity of the enzyme. The calbindin-binding peptide enriched from
the phage display library (SYSSIAKYPSHS) displays 75% identity with
residues 55-66 in IMPase (ISSIKEKYPSHS). Sequence identity is obtained
for residues 56-58 (SSI) and 61-66 (KYPSHS). The three-dimensional structure of IMPase (21) is a symmetric homodimer in which the side
chains of residues 61-66 are surface-exposed in an extended loop (Fig.
5). Residues 55-61 are at the end of an
IMPase is a key enzyme in the regulation of the activity of the PI
signaling pathway (Fig. 6), which is of
major importance in all eukaryotes. IMPase hydrolyzes IMP to produce
phosphate and myo-inositol, the starting material for
synthesis of PI, as well as phosphatidylinositol mono- and di-phophates
(PIP and PIP2), and subsequently IP3. IMPase
hence acts in the biosynthetic pathway leading from IMP to
IP3. IP3 is an agonist of the IP3
receptor, which is a Ca2+ channel in the endoplasmatic
reticulum. IP3 may stimulate the release of
Ca2+ from the endoplasmatic reticulum store to increase the
cytosolic Ca2+ levels, although the action of both
IP3 and Ca2+ on the IP3 receptor is
intricately coupled (22). The released Ca2+ ions bind to a
number of Ca2+ sensor proteins, e.g. calmodulin,
leading to the activation of a vast number of enzymes and cellular
events. IP3 is short-lived and rapidly depleted if not
newly synthesized; its half-life in neuronal cells may be as short as
100 ms (23). The enzymatic activity of IMPase is therefore required to
sustain the PI signaling pathway. The stimulatory effect of
calbindin on IMPase activity is apparently not regulated directly
by Ca2+ because IMPase is activated by calbindin both in
the absence and presence of Ca2+ (Fig. 4). This is in
striking contrast to the calmodulin system where target enzyme
regulation is Ca2+-dependent.
myo-Inositol Monophosphatase Is an Activated Target
of Calbindin D28k*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-D-thiogalactoside
and 5-bromo-4-chloro-3-indolyl-
-D-galactoside to obtain
plaques deriving from single phages. Sequencing templates were prepared
from individual plaques as described in the manual for the Ph.D.-12
Phage Display Peptide Library kit. DNA sequencing reactions were
performed in an Eppendorff Gradient Mastercycler using Big Dyes Cycle
Sequencing kit from Applied Biosystems and the sequencing primer. The
reaction products were separated on an ABI Prism 310 genetic analyzer
from Applied Biosystems.
F, was
plotted as a function of total calbindin exemplified in Fig. 1 for
excitation at 236 nm, and the data was fitted using the following equation.
with the free calbindin concentration, [CB], calculated
as follows.
(Eq. 1)
(Eq. 2)
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (13K):
[in a new window]
Fig. 1.
Fluorescence titration of 10 µM IMPase with calbindin. The
difference in fluorescence at 236 nm (
F) between the
mixture and spectral sum of IMPase and calbindin is plotted
versus total calbindin concentration (
). The solid
line shows the fit using Equations 1 and 2 with
KD = 0.9 µM. The experiment was
performed twice, and one of the replicates is shown.

View larger version (20K):
[in a new window]
Fig. 2.
Enzymatic activity of 0.02 µM IMPase in 50 mM
Hepes/KOH, 150 mM KCl, 2 mM
MgCl2, 0.1 mM EGTA at pH 7.1, and
37 °C. A, IMPase activity as a function of IMP
concentration, reported as the concentration of phosphate released per
minute in the absence (
) or presence (
) of 10 µM
calbindin. B, relative activity at different IMP
concentrations as a function of calbindin concentration. At each
substrate concentration, the activity is calculated relative to the
activity in the absence of calbindin. The experiments were performed
two times using double samples, and the deviations were less than
5%.

View larger version (13K):
[in a new window]
Fig. 3.
pH effect on the enzymatic activity of
0.02 µM IMPase in 50 mM
Hepes/KOH, 150 mM KCl, 2 mM
MgCl2, 0.1 mM EGTA at 37 °C.
A, IMPase activity as a function of pH, reported as the
concentration of phosphate released per minute in the absence (
) or
presence (
) of 10 µM calbindin. B, effect
of 10 µM calbindin as a function of pH. At each pH, the
activity in the presence of 10 µM calbindin is calculated
relative to the activity in the absence of calbindin. The experiments
were performed two times using double samples, and the deviations were
less than 5%.

View larger version (22K):
[in a new window]
Fig. 4.
IMPase activity as a function of free
Ca2+ concentration, in the absence (
) or presence (
)
of 10 µM calbindin at pH 7.1. The experiments were performed two times using double samples, and the
deviations were less than 5%.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-helix that may function to stabilize the loop. The two identical
55-66 sites are maximally separated in the structure such that the
homodimer may bind two calbindin molecules without steric hindrance
(calbindin, 30 kDa, is slightly smaller than the IMPase monomer, 32 kDa). These structural features make residues 55-66 an ideal site for protein-protein interaction. The 12-residue segment is strongly conserved. It is identical in IMPase of human, porcine, rat, and african clawed frog origin, whereas the bovine sequence has a Thr in
stead of Ser at position 57.

View larger version (58K):
[in a new window]
Fig. 5.
Three-dimensional structure of human
recombinant IMPase (21). The enzyme is a symmetric dimer, with one
monomer shown in red and the other one in
gray. The side-chains of residues 55-60 (ISSIKE) are
shown in yellow and residues 61-66 (KYPSHS) in
green in both subunits. The side chains of the active site
residues are shown in blue. Top, ribbon model
(side view). Middle (top view) and bottom (bottom
view), space-filling models with all heavy atoms displayed. The figure
was prepared with the program MOLMOL (29).

View larger version (12K):
[in a new window]
Fig. 6.
Phosphatidylinositol signaling pathway.
The pathway is schematically outlined to the right, and the
reaction catalyzed by IMPase is drawn in greater detail to the
left. I, inositol; IP,
myo-inositsol-1(or 4)-monophosphate (the 4-phosphate is
shown to the left, but the phosphate group in position 1 can
also be hydrolyzed); PI, phosphatidylinositol;
PIP2, phosphatidylinositol 4,5-bisphosphate;
IP, myo-inositol-monophosphate;
IP2, myo-inositol-bisphosphate;
IP3, myo-inositol-1,4,5-triphosphate;
DAG, diaglycerol; PKC, protein kinase C.
The calbindin gene expression is known to be up-regulated during cell stress (24-26). It is striking that the relative activation of IMPase by calbindin is largest during stress conditions such as low substrate concentration (Fig. 2) and during acidosis (Fig. 4). The latter condition often occurs as a side effect of Ca2+ entry. During cell stress conditions, calbindin may act as a survival molecule, which ensures the activity of IMPase under conditions at which the activity would otherwise be lost.
Lithium, carbamazepine, and valproic acid are effective
mood-stabilizing treatments for bipolar affective disorder. Recently, it has been shown that all these drugs act by causing cellular inositol
depletion (27). Based on these findings it was suggested that the
development of new therapies for bipolar disorder should focus on
inositol phosphate metabolism (27). Both IMPase and the IP3
receptor are considered attractive therapeutic targets for conditions
in which the amount of Ca2+/inositol signaling needs to be
controlled. It has been proposed that lithium inhibits IMPase, thereby
causing a depletion of inositol, reduced synthesis of PIs, and
attenuated PI-linked signal transduction (28). A serious drawback with
Li+ therapy is the narrow margin between the therapeutic
(0.5-1 mM) and toxic (> 2 mM) doses (28).
Li+ may interfere with the homeostasis of different
electrolytes and essential ions as well as ion transport. There is
considerable interest in finding novel regulators of IMPase with a
larger therapeutic concentration window and fewer side effects. The
discovery of calbindin as a potential cellular activator of IMPase
could be of interest in the development of novel pharmacological
treatments for conditions due to an imbalance of the
Ca2+/IP3 pathways. Substances may be
constructed that enhance or attenuate the activity of IMPase based on
its interaction with calbindin, for example by competing with either
protein for binding to the other one, by altering the affinity of
calbindin for IMPase, by altering rates of association and dissociation
of the two proteins, by altering the Ca2+-binding
properties of calbindin, by affecting the expression levels of
calbindin, or by otherwise affecting its ability to regulate
IMPase.
| |
ACKNOWLEDGEMENTS |
|---|
The generous gift of secretagogin and calretinin by Patrick Groves and Malgorzata Palczewska, Nencki Insitute, Warsaw is gratefully acknowledged.
| |
FOOTNOTES |
|---|
* This work was supported in part by Grant VR-M 11552 (to S. L.) from the Swedish Research Council and was sponsored by Salubrin Druvan (post doctoral fellowship, to T. B.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 46-46-2228246;
Fax: 46-46-2224543; E-mail: Sara.Linse@bpc.lu.se.
Published, JBC Papers in Press, August 9, 2002, DOI 10.1074/jbc.M203492200
2 E. Thulin and S. Linse, submitted for publication.
3 HIDYNNVS and SGIAQFHIDYNNVS are the sequences of two synthetic peptides derived from human vitamin K-dependent protein S (30), a plasma protein completely unrelated to calbindin.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: calbindin, calbindin D28k; IMP, myo-inositol-1-phosphate; IMPase, myo-inositol (1 or 4)-monophosphatase; PI, phosphatidylinositol; IP3, myo-inositol-1,4,5-triphosphate; PEG, polyethylene glycol.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Mikkonen, M., Soininen, H., and Pitkanen, A. (1997) J. Comp. Neurol. 388, 64-88[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Fortin, M., and Parent, A. (1997) J. Chem. Neuroanat. 14, 51-61[Medline] [Order article via Infotrieve] |
| 3. | Winsky, L., and Kuznicki, J. (1995) J. Neurochem. 65, 381-388[Medline] [Order article via Infotrieve] |
| 4. | Christakos, S., Gabrielides, C., and Rhoten, W. B. (1989) Endocr. Rev. 10, 3-26[Medline] [Order article via Infotrieve] |
| 5. |
Oberholtzer, J. C.,
Buettger, C.,
Summers, M. C.,
and Matschinsky, F. M.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
3387-3390 |
| 6. | Mattson, M. P., Rychlik, B., Chu, C., and Christakos, S. (1991) Neuron 6, 41-51[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Sloviter, R. S., Sollas, A. L., Barbaro, N. M., and Laxer, K. D. (1991) J. Comp. Neurol. 308, 381-396[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Sloviter, R. S. (1989) J. Comp. Neurol. 280, 183-196[CrossRef][Medline] [Order article via Infotrieve] |
| 9. |
Airaksinen, M. S.,
Eilers, J.,
Garaschuk, O.,
Thoenen, H.,
Konnerth, A.,
and Meyer, M.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
1488-1493 |
| 10. | Roberts, W. M. (1994) J. Neurosci. 14, 3246-3262[Abstract] |
| 11. | Chard, P. S., Bleakman, D., Christakos, S., Fullmer, C. S., and Miller, R. J. (1993) J. Physiol. (Lond) 472, 341-357[Medline] [Order article via Infotrieve] |
| 12. | Morgan, D. W., Welton, A. F., Heick, A. E., and Christakos, S. (1986) Biochem. Biophys. Res. Commun. 138, 547-553[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Bellido, T.,
Huening, M.,
Raval-Pandya, M.,
Manolagas, S. C.,
and Christakos, S.
(2000)
J. Biol. Chem.
275,
26328-26332 |
| 14. | Reisner, P. D., Christakos, S., and Vanaman, T. C. (1992) FEBS Lett. 297, 127-131[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Berggård, T., Silow, M., Thulin, E., and Linse, S. (2000) Biochemistry 39, 6864-6873[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Berridge, M. J., Downes, C. P., and Hanley, M. R. (1989) Cell 59, 411-419[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Thulin, E., and Linse, S. (1999) Protein Exprression Purif. 15, 265-270 |
| 18. | Itaya, K., and Ui, M. (1966) Clin. Chim. Acta. 14, 361-366[CrossRef][Medline] [Order article via Infotrieve] |
| 19. |
Gartner, W.,
Lang, W.,
Leutmetzer, F.,
Domanovits, H.,
Waldhausl, W.,
and Wagner, L.
(2001)
Cereb. Cortex
11,
1161-1169 |
| 20. |
Wagner, L.,
Oliyarnyk, O.,
Gartner, W.,
Nowotny, P.,
Groeger, M.,
Kaserer, K.,
Waldhausl, W.,
and Pasternack, M. S.
(2000)
J. Biol. Chem.
275,
24740-24751 |
| 21. |
Bone, R.,
Springer, J. P.,
and Atack, J. R.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
10031-10035 |
| 22. | Berridge, M. J., and Irvine, R. F. (1989) Nature 341, 197-205[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | Boekhoff, I., Tareilus, E., Strotmann, J., and Breer, H. (1990) EMBO J. 9, 2453-2458[Medline] [Order article via Infotrieve] |
| 24. | Lowenstein, D. H., Gwinn, R. P., Seren, M. S., Simon, R. P., and McIntosh, T. K. (1994) Brain Res. Mol. Brain Res. 22, 299-308[Medline] [Order article via Infotrieve] |
| 25. | Lowenstein, D. H., Miles, M. F., Hatam, F., and McCabe, T. (1991) Neuron 6, 627-633[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Lee, S., Williamson, J., Lothman, E. W., Szele, F. G., Chesselet, M. F., von Hagen, S., Sapolsky, R. M., Mattson, M. P., and Christakos, S. (1997) Brain Res. Mol. Brain Res. 47, 183-194[Medline] [Order article via Infotrieve] |
| 27. | Williams, R. S., Cheng, L., Mudge, A. W., and Harwood, A. J. (2002) Nature 417, 292-295[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Atack, J. R., Broughton, H. B., and Pollack, S. J. (1995) Trends Neurosci. 18, 343-349[CrossRef][Medline] [Order article via Infotrieve] |
| 29. | Koradi, R., Billeter, M., and Wuthrich, K. (1996) J. Mol. Graph. 14, 51-55[CrossRef][Medline] [Order article via Infotrieve] |
| 30. |
Giri, T. K.,
Linse, S.,
Garcia de Frutos, P.,
Yamazaki, T.,
Villoutreix, B. O.,
and Dahlback, B.
(2002)
J. Biol. Chem.
277,
15099-15106 |
This article has been cited by other articles:
![]() |
M. C. Bauer, H. Nilsson, E. Thulin, B. Frohm, J. Malm, and S. Linse Zn2+ binding to human calbindin D28k and the role of histidine residues Protein Sci., April 1, 2008; 17(4): 760 - 767. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ohnishi, H. Ohba, K.-C. Seo, J. Im, Y. Sato, Y. Iwayama, T. Furuichi, S.-K. Chung, and T. Yoshikawa Spatial Expression Patterns and Biochemical Properties Distinguish a Second myo-Inositol Monophosphatase IMPA2 from IMPA1 J. Biol. Chem., January 5, 2007; 282(1): 637 - 646. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Lynch, K. A. Dawson, and S. Linse Detecting Cryptic Epitopes Created by Nanoparticles Sci. Signal., March 21, 2006; 2006(327): pe14 - pe14. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Palczewska, G. Batta, P. Groves, S. Linse, and J. Kuznicki Characterization of calretinin I-II as an EF-hand, Ca2+, H+-sensing domain Protein Sci., July 1, 2005; 14(7): 1879 - 1887. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Schmidt, B. Schwaller, and J. Eilers Calbindin D28k targets myo-inositol monophosphatase in spines and dendrites of cerebellar Purkinje neurons PNAS, April 19, 2005; 102(16): 5850 - 5855. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |